CAS No.: 284461-73-0

Molecular formula: C21H16ClF3N4O3

Molecular weight: 464.82

Introduction: Sorafenib (trade name Dorgime) is a new drug for molecular targeted therapy. It is an oral multi-target, multi-kinase inhibitor that can target the serine/threonine kinase and receptor tyrosine kinase on tumor cells and tumor vessels. On the one hand, Sorafenib can inhibit the receptor tyrosine kinase KIT and FLT-3 as well as the serine/threonine kinase in the Raf/MEK/ERK pathway, and significantly inhibit the proliferation of tumor cells; On the other hand, tumor angiogenesis was significantly inhibited by upstream inhibition of receptor tyrosine kinase VEGFR and PDG-FR, and downstream inhibition of serine/threonine kinase in Raf/MEK/ERK pathway; That is, it can kill two birds with one stone and play a dual role in anti-angiogenesis and anti-tumor k cell proliferation.

Pharmacological action: sorafenib is a multi-kinase inhibitor. Preclinical studies have shown that sorafenib can simultaneously inhibit a variety of kinases present in cells and cell surfaces, including RAF kinase, vascular endothelial growth factor receptor-2 (VEGF-2), vascular endothelial growth factor receptor-3 (VEGF-3), and platelet-derived growth factor receptor- β (PDGFR- β)、 KIT and FLT-3. It can be seen that sorafenib has dual anti-tumor effects. On the one hand, it can directly inhibit tumor growth by inhibiting RAF/MEK/ERK signal transduction pathway; On the other hand, it can block the formation of tumor neovascularization by inhibiting VEGFR and PDGFR, and indirectly inhibit the growth of tumor cells.